Propanc Biopharma, Inc. — Form 10-Q Summary
Reporting period: Quarter ended March 31, 2024, the third quarter of the company’s fiscal 2024 year. The interim financial statements are unaudited and amounts are in U.S. dollars unless noted. The filing reports a preclinical-stage cancer-treatment business with no product revenue.
Business context and development
Propanc is developing PRP, a pro-enzyme formulation intended to treat cancers including pancreatic, ovarian and colorectal cancer. PRP remains preclinical. Management said it was preparing to advance PRP toward a first-in-human study in advanced cancer patients in 2024, but provided no firm timetable or financing commitment. The filing reports 83 granted, allowed or accepted patents and 10 additional patent applications filed or under examination.
Financial performance
| Metric | Three months ended March 31, 2024 | Three months ended March 31, 2023 | Nine months ended March 31, 2024 | Nine months ended March 31, 2023 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Operating expenses | $420,867 | $386,209 | $1,276,150 | $1,567,043 |
| Operating loss | $(420,867) | $(386,209) | $(1,276,150) | $(1,567,043) |
| Net loss | $(526,700) | $(809,809) | $(1,461,950) | $(1,912,522) |
| Net loss per share available to common stockholders | $(0.01) | $(0.42) | $(0.05) | $(2.08) |
With no revenue, gross margin is not meaningful. The nine-month net loss improved year over year, while interest expense rose to $575,837 from $418,579. A $372,371 gain from changes in derivative-liability fair value contributed to the reported nine-month results; this accounting gain is not operating revenue. Nine-month research and development expense declined to $195,712 from $242,223, which management attributed primarily to budget constraints.
Cash flow, liquidity and debt
- At March 31, 2024, cash was $6,222, current assets were $12,855 and current liabilities were $3,687,984. The resulting working-capital deficit was $3,675,129; total liabilities were $3,736,854.
- For the nine months, operating activities used $675,152 of cash and financing activities provided $690,920. Cash decreased by $3,825, from $10,047 at June 30, 2023.
- Current liabilities included $582,951 of convertible notes, $132,000 of note payable, $65,280 of loan payable, $1,187,714 of accounts payable and $765,828 of accrued expenses and other payables. Certain notes were past maturity or in default.
- Financing included convertible-note proceeds, related-party loans and a note issuance. Many notes have conversion prices linked to discounted or market-based share prices, creating potential dilution. At March 31, the company had 4.48 billion shares reserved for lender requirements.
Material changes, outlook and risks
- Common shares issued and outstanding rose from 6,031,250 at June 30, 2023 to 109,706,411 at March 31, 2024, largely through conversions of debt and warrants. The filing reports 167,978,843 shares outstanding as of May 13, 2024. It also describes 58,272,432 shares issued in April and May for debt conversions; the post-quarter share total reflects that issuance, so these amounts should not be added twice.
- Management and the financial statements state that substantial doubt exists about the company’s ability to continue as a going concern for at least 12 months from the report’s issuance. The company says it lacks cash to meet obligations over the next 12 months and depends on additional financing; no assurance is given that financing will be available on acceptable terms.
- As of the filing, certain debt remained in default, including convertible notes with $122,500 principal and a $132,000 promissory note. Subsequent to quarter-end, on May 7, 2024, the lender for the $132,000 note agreed to waive the 130% default repayment and extend maturity to September 30, 2024. The filing also reports post-quarter debt conversions.
- The company’s July 2023 equity-line agreement allows up to $5 million of potential purchases, subject to conditions including an effective registration statement and drawdown limits. This is a financing facility, not cash already available.
- Disclosure controls were deemed ineffective as of March 31, 2024. Reported material weaknesses include lack of documented controls, insufficient segregation of duties, no audit committee and inadequate financial-reporting review and U.S. GAAP expertise. Planned corrective steps depend on obtaining sufficient capital.
- The filing reports no material pending legal proceedings. It identifies no formal revenue guidance; development plans, financing needs and forward-looking statements remain subject to substantial uncertainty.
Most important facts for investors to verify
- Whether Propanc can secure enough financing to fund operations and development, and the terms, timing and dilution associated with any financing.
- The status and repayment or extension terms of all matured and defaulted notes, including the May 2024 extension, and the effect of interest, penalties and conversion provisions.
- Current shares outstanding, lender share reserves, and the potential impact of outstanding convertible debt and warrants on further dilution.
- Whether cash and working capital are sufficient to meet near-term obligations, given the $6,222 quarter-end cash balance and going-concern disclosure.
- Progress, funding and timing for PRP’s proposed first-in-human study, which remains a plan rather than a committed milestone.
- Whether management remediates the disclosed material weaknesses and improves disclosure controls and financial-reporting oversight.